EUVIMEDEUVIMED entdecken
CrossrefInfokarte

OM‐85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study

Mengting Sun, Yuqing Ni, Xueling Wu, Hao Tian, Yijun Song, Yinzhou Feng, Yunxin Guo, Yong Zhang, Jun Yin, Charles A. Powell, Chunxue Bai, Yuanlin Song, Dawei Yang

The Clinical Respiratory Journal · 2025-07 · 19 (7)

DOI: 10.1111/crj.70109 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction The current clinical management of pulmonary nodules relies heavily on CT follow‐up, without early intervention. This retrospective study investigated the efficacy of OM‐85, a standardized lysate of human respiratory bacteria, in the treatment of high‐risk pulmonary nodules detected by computed tomography (CT) in patients with chronic bronchitis. Methods This study included 72 patients (93 enrolled nodules) who underwent treatment with OM‐85 and a matched control group of 90 patients (111 control nodules). The primary endpoint included reduced size of high‐risk ground glass nodules based on thin‐layer CT scans during follow‐up. Flow cytometry, multiplex immunofluorescence (mIF) analysis, and scRNA‐seq data were employed to determine differences in the immune cell subsets between the treatment and control groups. Results Oral OM‐85 treatment significantly reduced lung nodule diameter ( p = 0.031), the risk probability of malignancy ( p = 0.003), and the likelihood of clinical disease progression ( p = 0.0091). The effects of OM‐85 treatment were more pronounced in older patients (> 65‐year‐old) ( p = 0.029) and those with longer follow‐up cycles (> 200 days) ( p = 0.011). The peripheral blood samples showed a significantly higher proportion of natural killer (NK) cells in the treatment group. Furthermore, mIF staining of the pulmonary nodules and scRNA‐seq data demonstrated a higher percentage of NK cells in the treatment group compared with the control group ( p = 0.0003). Conclusion OM‐85 reduced the size of high‐risk pulmonary nodules and decreased the risk of malignant probability and disease progression in patients with chronic bronchitis by increasing the proportion of NK cells. Therefore, OM‐85 is a potential drug for the treatment of high‐risk pulmonary nodules in patients with chronic bronchitis.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →